SAN FRANCISCO (Thomson Financial) - Alfacell Corp. late Wednesday said results from its Phase IIIB clinical trial for Onconase, which was being studied as a potential treatment for unresectable malignant mesothelioma, didn't meet the trial's primary endpoint.
Lawyer Central Also Recommends These Stories: